Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies

Inclusion Criteria:

* Patient \> 18 years old
* Patient naive from anti-EGFR treatment (gefitinib, erlotinib, afatinib, cetuximab panitumumab, osimertinib, alectinib et crizotinib, etc).
* NSCLC (non-small cell lung cancer) patients eligible to anti-EGFR as first line treatment (gefitinib, erlotinib,afatinib, etc)
* Colorectal cancer patients eligible to anti-EGFR as first line treatment (cetuximab, panitumumab,….)
* Head and Neck/ENT (Ear, Nose Troat) cancer patients eligible to anti-EGFR as first line treatment (cetuximab,…)
* Signed informed consent
* Social security affiliation

Exclusion Criteria:

* Pregnant or Breastfeeding patient
* Patient in age to procreate without an efficient contraceptive method
* Patient with previous experience of allergic or irritative contact dermatitis to components of the studied product
* Patient with dermatologic conditions that cannot permit the study of skin toxicity of anti-EGFR
* Patients under radiotherapy 8 days prior the inclusion date
* Patient under immunotherapy 8 days prior the inclusion date
* Patient with local or systemic antibiotic treatment for acne 8 days prior the inclusion date
* Patient with antihistamines treatment 8 days prior the inclusion date
* Patients taking NSAIDs or corticoids as chronic medication or that took NSAIDs or corticoids 5 days prior the inclusion date
* Participation to another interventional study
* Patient with an altered ECOG (Eastern Cooperative Oncology Group) state ( \>2)
* Patient deprived of liberty or subjected to guardianship
* Impossibility to track and follow patient for geographical, social or psychiatric reasons.